IGI, Mallinckrodt deal

Mallinckrodt granted IGI non-exclusive rights to launch a generic formulation of Pennsaid 1.5% diclofenac in the U.S. on March 28, 2015. The deal settles litigation regarding IGI’s ANDA submission to FDA for the generic formulation. Mallinckrodt markets Pennsaid, a topical NSAID gel formulation of diclofenac, to treat pain associated with osteoarthritis (OA) of the knee. ...